These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
14. FMS-like tyrosine kinase 3-internal tandem duplication tyrosine kinase inhibitors display a nonoverlapping profile of resistance mutations in vitro. von Bubnoff N; Engh RA; Aberg E; Sänger J; Peschel C; Duyster J Cancer Res; 2009 Apr; 69(7):3032-41. PubMed ID: 19318574 [TBL] [Abstract][Full Text] [Related]
15. Characterization of midostaurin as a dual inhibitor of FLT3 and SYK and potentiation of FLT3 inhibition against FLT3-ITD-driven leukemia harboring activated SYK kinase. Weisberg EL; Puissant A; Stone R; Sattler M; Buhrlage SJ; Yang J; Manley PW; Meng C; Buonopane M; Daley JF; Lazo S; Wright R; Weinstock DM; Christie AL; Stegmaier K; Griffin JD Oncotarget; 2017 Aug; 8(32):52026-52044. PubMed ID: 28881711 [TBL] [Abstract][Full Text] [Related]
16. Potentiation of antileukemic therapies by the dual PI3K/PDK-1 inhibitor, BAG956: effects on BCR-ABL- and mutant FLT3-expressing cells. Weisberg E; Banerji L; Wright RD; Barrett R; Ray A; Moreno D; Catley L; Jiang J; Hall-Meyers E; Sauveur-Michel M; Stone R; Galinsky I; Fox E; Kung AL; Griffin JD Blood; 2008 Apr; 111(7):3723-34. PubMed ID: 18184863 [TBL] [Abstract][Full Text] [Related]
17. Induction of cytotoxicity and apoptosis in FLT3 mutant expressing cells using novel pyrimido cyanoacrylates and quinoline derivatives. Sobhanifar MA; Mashkani B; Saadatmandzadeh M; Sadeghnia HR; Mousavi SH Biomed Pharmacother; 2018 Dec; 108():893-905. PubMed ID: 30372901 [TBL] [Abstract][Full Text] [Related]
18. Glucocorticoids enhance the antileukemic activity of FLT3 inhibitors in FLT3-mutant acute myeloid leukemia. Gebru MT; Atkinson JM; Young MM; Zhang L; Tang Z; Liu Z; Lu P; Dower CM; Chen L; Annageldiyev C; Sharma A; Imamura Kawasawa Y; Zhao Z; Miller BA; Claxton DF; Wang HG Blood; 2020 Aug; 136(9):1067-1079. PubMed ID: 32396937 [TBL] [Abstract][Full Text] [Related]
19. Using combination therapy to override stromal-mediated chemoresistance in mutant FLT3-positive AML: synergism between FLT3 inhibitors, dasatinib/multi-targeted inhibitors and JAK inhibitors. Weisberg E; Liu Q; Nelson E; Kung AL; Christie AL; Bronson R; Sattler M; Sanda T; Zhao Z; Hur W; Mitsiades C; Smith R; Daley JF; Stone R; Galinsky I; Griffin JD; Gray N Leukemia; 2012 Oct; 26(10):2233-44. PubMed ID: 22469781 [TBL] [Abstract][Full Text] [Related]
20. Drug resistance in mutant FLT3-positive AML. Weisberg E; Sattler M; Ray A; Griffin JD Oncogene; 2010 Sep; 29(37):5120-34. PubMed ID: 20622902 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]